BTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION)

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $58.00 price objective on the stock. BTIG Research’s target price would indicate a potential upside of 57.57% from the company’s previous close.

SION has been the subject of several other reports. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Lifesci Capital began coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. Finally, Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $45.43.

Sionna Therapeutics Stock Performance

Shares of SION stock opened at $36.81 on Wednesday. Sionna Therapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $45.00. The stock’s 50-day simple moving average is $40.46 and its 200-day simple moving average is $30.43. The firm has a market capitalization of $1.64 billion and a PE ratio of -7.56.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Insider Activity

In other news, Director Orbimed Advisors Llc sold 33,356 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the transaction, the director owned 3,561,655 shares of the company’s stock, valued at approximately $158,671,730.25. This trade represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Peter A. Thompson sold 33,356 shares of the business’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the transaction, the director directly owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. The trade was a 0.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,312,357 shares of company stock worth $50,469,863 in the last three months. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of large investors have recently made changes to their positions in SION. Goldman Sachs Group Inc. acquired a new stake in Sionna Therapeutics in the first quarter valued at approximately $667,000. Woodline Partners LP acquired a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $837,000. Aberdeen Group plc raised its holdings in shares of Sionna Therapeutics by 27.4% in the 2nd quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock valued at $16,492,000 after purchasing an additional 204,583 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Sionna Therapeutics in the second quarter valued at $45,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.